Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Hepatic Cirrhosis with ascites or lower extremities edema~2. Hospitalized patients~3. 18 years old\~75 years old~4. Inform Consent Form Signed~Exclusion Criteria:~1. Patients with any of the following diseases, complications or symptoms:~   * Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above);~  * Malignant ascites;~  * Spontaneous bacterial peritonitis;~  * Likely to have gastrointestinal bleeding during the study period;~  * Heart failure (NYHA Note 2 Class Ⅲ andⅣ);~  * Anuria (daily urine output below 100mL);~  * Dysuria induced by urinary tract stenosis, calculus, or tumor.~2. Patients with any of the following history:~   * With gastrointestinal bleeding within 10 days prior to screening;~  * With cerebrovascular accident within 1 month prior to screening;~  * With gout attack within 1 month prior to screening;~  * With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.).~3. Patients whose systolic blood pressure is below 90mmHg during screening;~4. Patients with abnormal values in the following lab examination indicators:~   Serum creatinine higher than 2.5 times the upper limit of normal range, serum Na+\>145mmol/L(or higher than the upper limit of normal range), serum K+\> 5.5 mmol/L, uric acid\>476µmol/L, child-Pugh score\>10~5. Patients ineligible for oral medication~6. Patients in pregnancy or lactation; female of childbearing potential not taking contraceptive measures;~7. Patients having taken blood products including albumin products within 4 days prior to application of investigational product;~8. Patients having participated in clinical trials of other drugs within 1 month prior to screening;~9. Patients used to participate in clinical trials of Tolvaptan and take the said drug;~10. Patients determined by the investigator as illegible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan 15mg tablet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).